Literature DB >> 25922085

Lyme neuroborreliosis in a patient treated with TNF-alpha inhibitor.

Maja Ivartnik Merkac1, Janez Tomazic2, Franc Strle3.   

Abstract

A 57-year-old woman, receiving TNF-alpha inhibitor adalimumab for psoriasis, presented with early Lyme neuroborreliosis (Bannwarth's syndrome). Discontinuation of adalimumab and 14-day therapy with ceftriaxone resulted in a smooth course and favorable outcome of Lyme borreliosis. This is the first report on Lyme neuroborreliosis in a patient treated with TNF-alpha inhibitor.

Entities:  

Keywords:  Adalimumab; Bannwarth’s syndrome; Lyme borreliosis; Lyme neuroborreliosis; TNF-α inhibitor

Mesh：

Substances：

Year:  2015        PMID： 25922085     DOI： 10.1007/s15010-015-0779-5

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  15 in total

Review 1.  Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.

Authors:  H Reiber; J B Peter
Journal:  J Neurol Sci       Date:  2001-03-01       Impact factor: 3.181

2.  Borreliosis in a patient treated with anti-TNFα therapy: first case.

Authors:  N Bonnet; S Guis; M Drancourt; P Brouqui; P Berbis
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-03       Impact factor: 6.166

3.  Lyme disease concurrent with human immunodeficiency virus infection.

Authors:  J C Garcia-Monco; H M Frey; B F Villar; M G Golightly; J L Benach
Journal:  Am J Med       Date:  1989-09       Impact factor: 4.965

4.  Lyme meningoradiculitis and myositis after allogeneic hematopoietic stem cell transplantation.

Authors:  Martín Rodríguez; Sherry Chou; David C Fisher; Umberto De Girolami; Anthony A Amato; Francisco M Marty
Journal:  Clin Infect Dis       Date:  2005-11-08       Impact factor: 9.079

5.  Seronegative Lyme neuroborreliosis in a patient on treatment for chronic lymphatic leukemia.

Authors:  T Harrer; W Geissdörfer; C Schoerner; E Lang; G Helm
Journal:  Infection       Date:  2007-04       Impact factor: 3.553

Review 6.  Lyme borreliosis.

Authors:  Gerold Stanek; Gary P Wormser; Jeremy Gray; Franc Strle
Journal:  Lancet       Date:  2011-09-06       Impact factor: 79.321

7.  The impact of immunosuppression on erythema migrans. A retrospective study of clinical presentation, response to treatment and production of Borrelia antibodies in 33 patients.

Authors:  B Fürst; M Glatz; H Kerl; R R Müllegger
Journal:  Clin Exp Dermatol       Date:  2006-07       Impact factor: 3.470

Review 8.  Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Authors:  Jasvinder A Singh; George A Wells; Robin Christensen; Elizabeth Tanjong Ghogomu; Lara Maxwell; John K Macdonald; Graziella Filippini; Nicole Skoetz; Damian Francis; Luciane C Lopes; Gordon H Guyatt; Jochen Schmitt; Loredana La Mantia; Tobias Weberschock; Juliana F Roos; Hendrik Siebert; Sarah Hershan; Michael Pt Lunn; Peter Tugwell; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

Review 9.  Infection risk and biologics: current update.

Authors:  Dinny Wallis
Journal:  Curr Opin Rheumatol       Date:  2014-07       Impact factor: 5.006

10.  Lyme neuroborreliosis in HIV-1 positive men successfully treated with oral doxycycline: a case series and literature review.

Authors:  Daniel Bremell; Christer Säll; Magnus Gisslén; Lars Hagberg
Journal:  J Med Case Rep       Date:  2011-09-19
View more
  3 in total

Review 1.  Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience.

Authors:  Paul Sator
Journal:  Ther Adv Chronic Dis       Date:  2018-05-22       Impact factor: 5.091

Review 2.  A joint effort: The interplay between the innate and the adaptive immune system in Lyme arthritis.

Authors:  Michelle A E Brouwer; Freek R van de Schoor; Hedwig D Vrijmoeth; Mihai G Netea; Leo A B Joosten
Journal:  Immunol Rev       Date:  2020-01-13       Impact factor: 12.988

3.  Early Lyme Borreliosis in Patients Treated with Tumour Necrosis Factor-Alfa Inhibitors.

Authors:  Vera Maraspin; Petra Bogovič; Tereza Rojko; Katarina Ogrinc; Eva Ružić-Sabljić; Franc Strle
Journal:  J Clin Med       Date:  2019-11-02       Impact factor: 4.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.